Dimension Therapeutics Elects Industry Veteran And Finance Officer George Migausky To Its Board Of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced the election of George Migausky to the Company's Board of Directors. Mr. Migausky brings more than 30 years of senior financial management experience with high-growth life science and technology companies. His election to Dimension's Board is effective immediately, and he will chair the newly established audit committee.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.